Business Services Industry

Gore Horvath Announces Investment Opinion on Trimedyne Inc

Business Wire, April 1, 1999

IRVINE, Calif.--(BUSINESS WIRE)--April 1, 1999--

Research Report on Trimedyne Issued by Gore Horvath

Trimedyne Inc. (Nasdaq:TMED) Thursday announced the issuance of a Research Report and Speculative Buy Recommendation on Trimedyne by Gore Horvath, an investment banking firm with headquarters in Long Beach, Calif.

The Gore Horvath report notes the advantages Trimedyne's "cold" Holmium lasers enjoy over competing medical lasers in urology, orthopedic, ENT, gynecology and general surgery.

The report also stresses the potential value of the revolutionary, ECG synchronized Gene Injection and Laser Revascularization System to treat coronary artery disease being developed by Cardiodyne Inc., a 90 percent owned subsidiary of Trimedyne.

Copies of the report are available from Gore Horvath by calling 800/965-8284.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act: With the exception of any historical information contained in this release, the matters described herein may contain forward-looking statements that involve risk and uncertainties that may, individually or mutually, impact the matters herein described. Such risks may be outside the control of the company, and may be detailed from time to time in the company's periodic SEC reports.

COPYRIGHT 1999 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
Click Here
advertisement
  • Click Here
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale